Entero Healthcare Ltd - Organic growth takes centre stage; margin expansion accelerates | Q1FY27 Company Update

Entero Healthcare Solutions delivered a strong Q1FY27 performance, with revenue coming in ahead of our estimates, supported by robust organic growth and continued scale-up of the existing distribution platform. More importantly, profitability remained the key highlight, with EBITDA margins reaching 5.0% in Q1 itself, thereby achieving the company’s full-year FY27 guidance, supported by procurement efficiencies, improving business mix and rationalisation of low-margin businesses. We remain constructive on Entero’s medium-term growth trajectory, with management confident of sustaining ~20% growth even without meaningful incremental acquisitions, while increasing wallet share, scaling the higher-margin MedTech business and operating leverage provide further headroom for margin expansion. We largely maintain our FY27E revenue estimates and increase FY28E revenue by 3.4%; factoring in ~30bps higher margins, we raise our EBITDA estimates by 3.0%/9.4% and PAT estimates by 2.9%/9.7% for FY27E/FY28E, respectively. We also introduce FY29E estimates and roll forward our valuation to Q1FY29E, valuing the stock at 25x P/E to arrive at a revised Target Price of Rs 1,645 (earlier Rs 1,440).

Entero Healthcare Ltd. Stock Price Chart

Revenue – Strong growth momentum continues:

Entero Healthcare Solutions reported robust revenue growth of 38.2% YoY to Rs 19,405 mn in Q1FY27. Organic revenue growth stood at 17.8% on a reported basis and 19.6% on a like-for-like basis, materially ahead of the underlying pharmaceutical market, reflecting sustained wallet-share gains and deeper penetration across the existing customer base. Inorganic growth of 20.4% was entirely driven by the calendarization of acquisitions completed in the previous year, with no new acquisitions undertaken during Q1FY27. Management also highlighted that reported growth was impacted by ~2.5% due to the deliberate exit from certain low-margin businesses.

Best-ever Margins:

Gross margin expanded by 108bps YoY to 11.4%, while OPM improved by 144bps YoY and 49bps QoQ to a best-ever 5.0%, supported by procurement efficiencies, operating leverage, improving business mix and rationalisation of low-margin businesses. Consequently, EBITDA increased 93.7% YoY and 12.7% QoQ to Rs 969.9 mn. PAT attributable to owners, after minority interest, stood at ~Rs 380 mn, with minority interest accounting for ~27% of consolidated profit.

Outlook:

We remain positive on Entero’s medium-term outlook, supported by sustained organic growth, continued wallet-share gains and increasing monetisation of the distribution platform built over the past few years. Management remains confident of delivering ~20% growth over the medium term even without meaningful incremental acquisitions, with future growth increasingly driven by organic opportunities on the existing platform rather than M&A-led expansion. The higher contribution from MedTech, procurement efficiencies and operating leverage should provide further headroom for margin expansion. With OPM already reaching 5.0% in Q1FY27 and management indicating aspirations above 6% over the medium term, we expect earnings growth to remain ahead of topline growth, alongside continued improvement in return ratios and cash generation

Valuation and key risk

We factor in Revenue/EBITDA/PAT after MI CAGR of ~20%/~42%/~55% over FY26–29E, led by healthy organic growth, MedTech scale-up and margin expansion. While FY27E growth should benefit from organic momentum and calendarization of past acquisitions, FY28E/FY29E growth should normalise towards the company’s organic trajectory, while remaining ahead of IPM growth, supported by wallet-share gains and deeper platform penetration. We largely maintain FY27E revenue estimates, upgrade FY28E revenue by 3.4% and raise margin assumptions by ~30bps. We introduce FY29E estimates and roll forward our valuation to Q1FY29E, valuing Entero at 25x P/E to arrive at a TP of Rs 1,645 (Rs 1,440). Key risks include slower organic growth, higher minority interest, working-capital deterioration and slower MedTech ramp-up.

Company website: https://www.enterohealthcare.com/

*CMP is as per report published date

Click to download the full Entero Healthcare Ltd Q1FY27 Company Update

Analyst:

• Rahul Dani - Research Analyst, Institutional Equities (NISM-201500034725)
• Riya Shah - Research Associate, Institutional Equities (NISM-201800191080)

Open your MNCL Demat Account

FAQs on Entero Healthcare Ltd Q1FY27 Company Update

These FAQs summarize key insights from MNCL’s institutional equity research on Entero Healthcare, highlighting performance trends, growth drivers and key risks.

How did Entero Healthcare perform in Q1FY27?

Entero Healthcare reported revenue growth of 38.2% YoY to ₹19.4 billion. EBITDA increased 93.7% YoY to approximately ₹970 million, while OPM reached a best-ever 5.0%.

What drove Entero Healthcare's revenue growth?

Growth was supported by strong organic expansion, wallet-share gains, deeper customer penetration and the calendarisation of acquisitions completed during the previous year.

What drove Entero Healthcare's margin improvement?

Margin expansion was supported by procurement efficiencies, operating leverage, an improving business mix and the rationalisation of selected low-margin businesses.

What is Entero Healthcare's growth outlook?

Management remains confident of approximately 20% medium-term growth even without meaningful incremental acquisitions. Organic growth, wallet-share gains and deeper platform penetration are expected to become increasingly important.

Can MedTech support Entero Healthcare's margins?

Yes. The increasing contribution from the higher-margin MedTech business, combined with procurement efficiencies and operating leverage, could provide additional scope for margin expansion.

What is the target price for Entero Healthcare?

The supplied research report maintains a Buy rating and assigns a target price of ₹1,645 versus the reported CMP of ₹1,315. This is an analyst estimate and does not guarantee future returns.

What are the key risks for Entero Healthcare?

Key risks include slower organic growth, higher minority interest, deterioration in working capital and slower-than-expected scaling of the MedTech business.

Before You Trade, Strengthen Your Foundations with These Guides

• For a stronger understanding of indicators such as RSI, VWAP, and trendlines, check our 👉 Technical Analysis Fundamentals section.
• Want to refine your risk-reward planning? Explore our insights on 👉 Position Sizing & Risk Management Strategies.
• Read more research reports on Entero Healthcare Stock